Over the last decades, there have been major advancements in the field of renal replacement therapy (RRT) with utilization of newer technologies and advent of various modalities. Once exclusively used for treatment of renal failure and its metabolic consequences, the science of RRT has expanded to include non-renal indications such as treatment of fluid overload in patients with refractory heart failure. Hepatic encephalopathy due to sudden rise in serum ammonia level in the setting of acute liver failure represents an underexplored area in which RRT can potentially be helpful. While the key role of hyperammonemia in the pathogenesis of hepatic encephalopathy in patients with liver failure is well established, emerging data points to distinct pathophysiologic mechanisms underlying chronic alterations in neural metabolic functions and acute changes in cerebral perfusion. In the acute setting, ammonia can cross the blood–brain barrier at high levels leading to sudden formation of strong osmolytes, significant transcellular shift of water, and cerebral edema. Herein, we provide a brief overview of the role of RRT in management of acute hyperammonemia in the setting of acute liver failure and discuss the practical aspects of the available therapeutic modalities. Larger studies are needed to shed light on a number of clinical aspects such as the impact on the outcomes, criteria for selection of the patients that would benefit most from this therapeutic approach, optimal timing of initiation of RRT, and the most appropriate modality.

1.
Slack AJ, Auzinger G, Willars C, Dew T, Musto R, Corsilli D, Sherwood R, Wendon JA, Bernal W: Ammonia clearance with haemofiltration in adults with liver disease. Liver Int 2014; 34: 42–48.
2.
Bajaj JS, Reddy KR, Tandon P, Wong F, Kamath PS, Garcia-Tsao G: The 3-month readmission rate remains unacceptably high in a large North American cohort of patients with cirrhosis. Hepatology 2016; 64: 200–208.
3.
Wijdicks EF: Hepatic encephalopathy. N Engl J Med 2016; 375: 1660–1670.
4.
Butterworth RF: Pathogenesis of hepatic encephalopathy and brain edema in acute liver failure. J Clin Exp Hepatol 2015; 5(suppl 1):S96–S103.
5.
Clemmesen JO, Larsen FS, Kondrup J, Hansen BA, Ott P: Cerebral herniation in patients with acute liver failure is correlated with arterial ammonia concentration. Hepatology 1999; 29: 648–653.
6.
Bernal W, Wendon J: Acute liver failure. N Engl J Med 2013; 369: 2525–2534.
7.
Bajaj JS, Gillevet PM, Patel NR, Ahluwalia V, Ridlon JM, Kettenmann B, Schubert CM, Sikaroodi M, Heuman DM, Crossey MM, Bell DE, Hylemon PB, Fatouros PP, Taylor-Robinson SD: A longitudinal systems biology analysis of lactulose withdrawal in hepatic encephalopathy. Metab Brain Dis 2012; 27: 205–215.
8.
Tsipotis E, Shuja A, Jaber BL: Albumin dialysis for liver failure: a systematic review. Adv Chronic Kidney Dis 2015; 22: 382–390.
9.
Ronco C, Tetta C: Extracorporal blood purification: more than diffusion and convection. Does this help? Curr Opin Crit Care 2007; 13: 662–667.
10.
Nalesso F, Brendolan A, Crepaldi C, Cruz D, de Cal M, Bellomo R, Ronco C: Albumin dialysis and plasma filtration adsorption dialysis system. Contrib Nephrol 2007; 156: 411–418.
11.
Meola M, Nalesso F, Petrucci I, Samoni S, Ronco C: Clinical Scenarios in Acute Kidney Injury: Hepatorenal Syndrome. Contrib Nephrol 2016; 188: 33–38.
12.
Ronco C: Continuous renal replacement therapy: forty-year anniversary. Int J Artif Organs 2017; 40: 257–264.
13.
Ronco C, Ricci Z, De Backer D, Kellum JA, Taccone FS, Joannidis M, Pickkers P, Cantaluppi V, Turani F, Saudan P, Bellomo R, Joannes-Boyau O, Antonelli M, Payen D, Prowle JR, Vincent JL: Renal replacement therapy in acute kidney injury: controversy and consensus. Crit Care 2015; 19: 146.
14.
Kellum JA, Bellomo R, Mehta R, Ronco C: Blood purification in non-renal critical illness. Blood Purif 2003; 21: 6–13.
15.
Kramer L, Tribl B, Gendo A, Zauner C, Schneider B, Ferenci P, Madl C: Partial pressure of ammonia versus ammonia in hepatic encephalopathy. Hepatology 2000; 31: 30–34.
16.
Cordoba J, Blei AT, Mujais S: Determinants of ammonia clearance by hemodialysis. Artif Organs 1996; 20: 800–803.
17.
Davenport A, Will EJ, Davison AM: Early changes in intracranial pressure during haemofiltration treatment in patients with grade 4 hepatic encephalopathy and acute oliguric renal failure. Nephrol Dial Transplt1990; 5: 192–198.
18.
Gardère JJ, Castaing Y, Gbikpi-Bénissan G: [Hemodialysis with a high permeability membrane in the treatment of encephalopathy of fulminant hepatitis]. Ann Fr Anesth Reanim 1987; 6: 423–428.
19.
Gupta S, Fenves AZ, Hootkins R: The Role of RRT in Hyperammonemic Patients. Clin J Am Soc Nephrol. 2016; 11: 1872–1878.
20.
Anwar S, Gupta D, Ashraf MA, Khalid SA, Rizvi SM, Miller BW, Brennan DC: Symptomatic hyperammonemia after lung transplantation: Lessons learnt. Hemodial Int 2014; 18: 185–191.
21.
Ghannoum M, Laliberte´ M, Nolin TD, MacTier R, Lavergne V, Hoffman RS, Gosselin S; EXTRIP Workgroup: Extracorporeal treatment for valproic acid poisoning: Systematic review and recommendations from the EXTRIP workgroup. Clin Toxicol (Phila) 2015; 53: 454–465.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.